r837 Invivogen Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    InvivoGen r837
    R837, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 214 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/r837/product/InvivoGen
    Average 99 stars, based on 214 article reviews
    Price from $9.99 to $1999.99
    r837 - by Bioz Stars, 2020-01
    99/100 stars
      Buy from Supplier

    75
    InvivoGen r837 tlrl imq
    R837 Tlrl Imq, supplied by InvivoGen, used in various techniques. Bioz Stars score: 75/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/r837 tlrl imq/product/InvivoGen
    Average 75 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    r837 tlrl imq - by Bioz Stars, 2020-01
    75/100 stars
      Buy from Supplier

    83
    InvivoGen tlr7 ligand r837
    Immunization with nanoparticles containing <t>MPL+R837</t> induces persistent GCs and long lived antibody forming cells in draining lymph nodes a) C57BL/6 mice were immunized with OVA encapsulated in nanoparticles with MPL+R837 plus antigen. 4 weeks post primary immunization draining lymph nodes were excised, tissue sections prepared and stained for GCs (GL-7 red, B220 blue and IgG green). Images are representative of 2 independent experiments with draining lymph nodes obtained from at 2–3 mice per treatment condition per experiment. b) GCs were counted in LN sections at the time points indicated and represented as mean ± s.e.m from 4–6 draining lymph nodes from n=2–3 mice/treatment group. c) ELISPOT assay. Combination of TLR4 and <t>TLR7</t> ligands has no effect on the short lived ASCs, but stimulates long lived ASCs that persist for ~1.5 years. Graph represents average spots per 1 × 10 6 total lymph node cells ± s.e.m from duplicate cultures per treatment group. Data is representative of at least 2–3 independent experiments per time point indicated.
    Tlr7 Ligand R837, supplied by InvivoGen, used in various techniques. Bioz Stars score: 83/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tlr7 ligand r837/product/InvivoGen
    Average 83 stars, based on 30 article reviews
    Price from $9.99 to $1999.99
    tlr7 ligand r837 - by Bioz Stars, 2020-01
    83/100 stars
      Buy from Supplier

    85
    InvivoGen tlr7a
    Immunization with nanoparticles containing <t>MPL+R837</t> induces persistent GCs and long lived antibody forming cells in draining lymph nodes a) C57BL/6 mice were immunized with OVA encapsulated in nanoparticles with MPL+R837 plus antigen. 4 weeks post primary immunization draining lymph nodes were excised, tissue sections prepared and stained for GCs (GL-7 red, B220 blue and IgG green). Images are representative of 2 independent experiments with draining lymph nodes obtained from at 2–3 mice per treatment condition per experiment. b) GCs were counted in LN sections at the time points indicated and represented as mean ± s.e.m from 4–6 draining lymph nodes from n=2–3 mice/treatment group. c) ELISPOT assay. Combination of TLR4 and <t>TLR7</t> ligands has no effect on the short lived ASCs, but stimulates long lived ASCs that persist for ~1.5 years. Graph represents average spots per 1 × 10 6 total lymph node cells ± s.e.m from duplicate cultures per treatment group. Data is representative of at least 2–3 independent experiments per time point indicated.
    Tlr7a, supplied by InvivoGen, used in various techniques. Bioz Stars score: 85/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tlr7a/product/InvivoGen
    Average 85 stars, based on 9 article reviews
    Price from $9.99 to $1999.99
    tlr7a - by Bioz Stars, 2020-01
    85/100 stars
      Buy from Supplier

    88
    InvivoGen tlr7 agonist r837
    MV induces IFN-α and TRAIL expression following RLR activation in CD1c + DCs and <t>RLR/TLR7</t> activation in pDCs. (A) pDCs were pretreated or not with IRS661 (TLR7 inhibitor) or with MRT67307 (TBK1 and IKK-ε inhibitor) and then cultured with IL3, IL3+MV or <t>R837.</t> (B) CD1c + DCs were pretreated or not with IRS661 or MRT67307 and then cultured alone (−) or with MV. (C) pDCs were cultured with IL3+MV or with IL3+UV-inactivated MV (MV UV*) and CD1c + DCs were cultured alone (−), with MV or MV UV*. (D) pDCs and CD1c + DCs were exposed to 5′-ppp-dsRNA LyoVec, a RIG-I agonist. (A–D) IFN-α secretion was measured by ELISA. #, values are below the limit of detection of the kit (7 pg/mL). The expression of TRAIL by the indicated cells was determined by flow cytometry. Results are expressed as the mean ± SEM of three independent experiments. (A, B) * p
    Tlr7 Agonist R837, supplied by InvivoGen, used in various techniques. Bioz Stars score: 88/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tlr7 agonist r837/product/InvivoGen
    Average 88 stars, based on 12 article reviews
    Price from $9.99 to $1999.99
    tlr7 agonist r837 - by Bioz Stars, 2020-01
    88/100 stars
      Buy from Supplier

    97
    InvivoGen tlr ligands
    Cell-Based <t>TLR</t> Activation Assays. Various CEP adducts and TLR agonists were tested in HEK293 or THP-1 cells. Readouts were NFkB reporter signal or IL-8 secretion (columns), as indicated. In addition, the same wells were analyzed for viability with the CellTiter-Glo kit (axis on right; square symbols) to ensure that any lack of activation was not due to cell toxicity. HEK293 cells were treated with the following reagents: <t>HSA-CTL1,</t> HSA-CTL2, or HSA-CEP: 0, 3.9, 7.8, 15.6, 32.6, 62.5, and 125 and 250 µg/ml; Pam3CSK4∶ 0, 1.5, 3.2, 6.3, 12.5, 25, 50, 100 ng/mL. THP-1 cells were treated with the following reagents: HSA-CTL1, HSA-CTL2, or HSA-CEP: 62.5, 125, and 250 µg/mL; Pam3CSK4∶ 4, 20, and 100 ng/mL; FSL-1∶0.4, 2, and 10 ng/mL; LPS: 4, 20, and 100 ng/mL; R837 or R848∶0.4, 2, and 10 µM; ODN2006G5∶0.2, 1, and 5 µM.
    Tlr Ligands, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 524 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tlr ligands/product/InvivoGen
    Average 97 stars, based on 524 article reviews
    Price from $9.99 to $1999.99
    tlr ligands - by Bioz Stars, 2020-01
    97/100 stars
      Buy from Supplier

    Image Search Results


    Immunization with nanoparticles containing MPL+R837 induces persistent GCs and long lived antibody forming cells in draining lymph nodes a) C57BL/6 mice were immunized with OVA encapsulated in nanoparticles with MPL+R837 plus antigen. 4 weeks post primary immunization draining lymph nodes were excised, tissue sections prepared and stained for GCs (GL-7 red, B220 blue and IgG green). Images are representative of 2 independent experiments with draining lymph nodes obtained from at 2–3 mice per treatment condition per experiment. b) GCs were counted in LN sections at the time points indicated and represented as mean ± s.e.m from 4–6 draining lymph nodes from n=2–3 mice/treatment group. c) ELISPOT assay. Combination of TLR4 and TLR7 ligands has no effect on the short lived ASCs, but stimulates long lived ASCs that persist for ~1.5 years. Graph represents average spots per 1 × 10 6 total lymph node cells ± s.e.m from duplicate cultures per treatment group. Data is representative of at least 2–3 independent experiments per time point indicated.

    Journal: Nature

    Article Title: Programming the magnitude and persistence of antibody responses with innate immunity

    doi: 10.1038/nature09737

    Figure Lengend Snippet: Immunization with nanoparticles containing MPL+R837 induces persistent GCs and long lived antibody forming cells in draining lymph nodes a) C57BL/6 mice were immunized with OVA encapsulated in nanoparticles with MPL+R837 plus antigen. 4 weeks post primary immunization draining lymph nodes were excised, tissue sections prepared and stained for GCs (GL-7 red, B220 blue and IgG green). Images are representative of 2 independent experiments with draining lymph nodes obtained from at 2–3 mice per treatment condition per experiment. b) GCs were counted in LN sections at the time points indicated and represented as mean ± s.e.m from 4–6 draining lymph nodes from n=2–3 mice/treatment group. c) ELISPOT assay. Combination of TLR4 and TLR7 ligands has no effect on the short lived ASCs, but stimulates long lived ASCs that persist for ~1.5 years. Graph represents average spots per 1 × 10 6 total lymph node cells ± s.e.m from duplicate cultures per treatment group. Data is representative of at least 2–3 independent experiments per time point indicated.

    Article Snippet: MPL (detoxified lipid A, Avanti Lipids, Alabaster, AL) was dissolved in chloroform at 5mgs/ml and TLR7 ligand R837 (Invivogen, CA) was dissolved at 10–20mg/ml in DMSO with heating.

    Techniques: Mouse Assay, Staining, Enzyme-linked Immunospot

    MV induces IFN-α and TRAIL expression following RLR activation in CD1c + DCs and RLR/TLR7 activation in pDCs. (A) pDCs were pretreated or not with IRS661 (TLR7 inhibitor) or with MRT67307 (TBK1 and IKK-ε inhibitor) and then cultured with IL3, IL3+MV or R837. (B) CD1c + DCs were pretreated or not with IRS661 or MRT67307 and then cultured alone (−) or with MV. (C) pDCs were cultured with IL3+MV or with IL3+UV-inactivated MV (MV UV*) and CD1c + DCs were cultured alone (−), with MV or MV UV*. (D) pDCs and CD1c + DCs were exposed to 5′-ppp-dsRNA LyoVec, a RIG-I agonist. (A–D) IFN-α secretion was measured by ELISA. #, values are below the limit of detection of the kit (7 pg/mL). The expression of TRAIL by the indicated cells was determined by flow cytometry. Results are expressed as the mean ± SEM of three independent experiments. (A, B) * p

    Journal: Oncoimmunology

    Article Title: Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells

    doi: 10.1080/2162402X.2016.1261240

    Figure Lengend Snippet: MV induces IFN-α and TRAIL expression following RLR activation in CD1c + DCs and RLR/TLR7 activation in pDCs. (A) pDCs were pretreated or not with IRS661 (TLR7 inhibitor) or with MRT67307 (TBK1 and IKK-ε inhibitor) and then cultured with IL3, IL3+MV or R837. (B) CD1c + DCs were pretreated or not with IRS661 or MRT67307 and then cultured alone (−) or with MV. (C) pDCs were cultured with IL3+MV or with IL3+UV-inactivated MV (MV UV*) and CD1c + DCs were cultured alone (−), with MV or MV UV*. (D) pDCs and CD1c + DCs were exposed to 5′-ppp-dsRNA LyoVec, a RIG-I agonist. (A–D) IFN-α secretion was measured by ELISA. #, values are below the limit of detection of the kit (7 pg/mL). The expression of TRAIL by the indicated cells was determined by flow cytometry. Results are expressed as the mean ± SEM of three independent experiments. (A, B) * p

    Article Snippet: DCs were also cultivated with the TLR7 agonist R837 (1 µg/mL, Invivogen), exogenous type I IFNs (rhIFN-α-2a and rhIFN-β-1a, 100 ng/mL, ImmunoTools) or the RIG-I agonist 5′-ppp-dsRNA LyoVec (10 µg/mL, Invivogen).

    Techniques: Expressing, Activation Assay, Cell Culture, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Cytometry

    MV induces TRAIL expression and IFN-α secretion by pDCs and CD1c + DCs. pDCs were cultured with IL3, IL3+MV or the TLR7 agonist R837 (A). CD1c + DCs were cultured alone (−), with MV or R837 (B). The expression of surface markers by the indicated cells was determined by flow cytometry. IFN-α secretion was measured by ELISA. #, values are below the limit of detection of the kit (7 pg/mL). Results are expressed as the mean ± SEM of three independent experiments. * p

    Journal: Oncoimmunology

    Article Title: Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells

    doi: 10.1080/2162402X.2016.1261240

    Figure Lengend Snippet: MV induces TRAIL expression and IFN-α secretion by pDCs and CD1c + DCs. pDCs were cultured with IL3, IL3+MV or the TLR7 agonist R837 (A). CD1c + DCs were cultured alone (−), with MV or R837 (B). The expression of surface markers by the indicated cells was determined by flow cytometry. IFN-α secretion was measured by ELISA. #, values are below the limit of detection of the kit (7 pg/mL). Results are expressed as the mean ± SEM of three independent experiments. * p

    Article Snippet: DCs were also cultivated with the TLR7 agonist R837 (1 µg/mL, Invivogen), exogenous type I IFNs (rhIFN-α-2a and rhIFN-β-1a, 100 ng/mL, ImmunoTools) or the RIG-I agonist 5′-ppp-dsRNA LyoVec (10 µg/mL, Invivogen).

    Techniques: Expressing, Cell Culture, Flow Cytometry, Cytometry, Enzyme-linked Immunosorbent Assay

    Cell-Based TLR Activation Assays. Various CEP adducts and TLR agonists were tested in HEK293 or THP-1 cells. Readouts were NFkB reporter signal or IL-8 secretion (columns), as indicated. In addition, the same wells were analyzed for viability with the CellTiter-Glo kit (axis on right; square symbols) to ensure that any lack of activation was not due to cell toxicity. HEK293 cells were treated with the following reagents: HSA-CTL1, HSA-CTL2, or HSA-CEP: 0, 3.9, 7.8, 15.6, 32.6, 62.5, and 125 and 250 µg/ml; Pam3CSK4∶ 0, 1.5, 3.2, 6.3, 12.5, 25, 50, 100 ng/mL. THP-1 cells were treated with the following reagents: HSA-CTL1, HSA-CTL2, or HSA-CEP: 62.5, 125, and 250 µg/mL; Pam3CSK4∶ 4, 20, and 100 ng/mL; FSL-1∶0.4, 2, and 10 ng/mL; LPS: 4, 20, and 100 ng/mL; R837 or R848∶0.4, 2, and 10 µM; ODN2006G5∶0.2, 1, and 5 µM.

    Journal: PLoS ONE

    Article Title: Lack of Involvement of CEP Adducts in TLR Activation and in Angiogenesis

    doi: 10.1371/journal.pone.0111472

    Figure Lengend Snippet: Cell-Based TLR Activation Assays. Various CEP adducts and TLR agonists were tested in HEK293 or THP-1 cells. Readouts were NFkB reporter signal or IL-8 secretion (columns), as indicated. In addition, the same wells were analyzed for viability with the CellTiter-Glo kit (axis on right; square symbols) to ensure that any lack of activation was not due to cell toxicity. HEK293 cells were treated with the following reagents: HSA-CTL1, HSA-CTL2, or HSA-CEP: 0, 3.9, 7.8, 15.6, 32.6, 62.5, and 125 and 250 µg/ml; Pam3CSK4∶ 0, 1.5, 3.2, 6.3, 12.5, 25, 50, 100 ng/mL. THP-1 cells were treated with the following reagents: HSA-CTL1, HSA-CTL2, or HSA-CEP: 62.5, 125, and 250 µg/mL; Pam3CSK4∶ 4, 20, and 100 ng/mL; FSL-1∶0.4, 2, and 10 ng/mL; LPS: 4, 20, and 100 ng/mL; R837 or R848∶0.4, 2, and 10 µM; ODN2006G5∶0.2, 1, and 5 µM.

    Article Snippet: Thp1 (ATCC, cat# TIB-202) was primed with 0.5% DMSO for overnight, at 100,000/well, then incubate with HSA-CEP for 24 hr, with TLR ligands (Pam3CSK4, FSL1, R837 and R848 were all from Invivogen; LPS was purchased from Sigma) as controls.

    Techniques: Activation Assay